Letter: Cardiovascular risk of tenofovir disoproxil fumarate or tenofovir alafenamide fumarate in patients with chronic hepatitis B: More questions than an answer - author's reply

被引：1
|
作者：
Hong, Hyeyeon [1 ]
Choi, Jonggi [1 ]
机构：
[1] Univ Ulsan, Liver Ctr, Asan Med Ctr, Dept Gastroenterol,Coll Med, Seoul, South Korea
来源：
CLINICAL AND MOLECULAR HEPATOLOGY | 2024年 / 30卷 / 02期
基金：
新加坡国家研究基金会;
关键词：
Antiviral agent; Tenofovir; Lipid; DOUBLE-BLIND; PHASE-3;
D O I：
10.3350/cmh.2024.0123
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [31] REAL WORLD COMPARISON OF RENAL SAFETY IN PATIENTS TREATED WITH TENOFOVIR DISOPROXIL FUMARATE VS TENOFOVIR ALAFENAMIDE FOR CHRONIC HEPATITIS B
    Zhang, Xueyun
    Hu, Qiankun
    Liu, Xiaoqin
    Huang, Yuxian
    HEPATOLOGY, 2021, 74 : 490A - 491A
  • [32] Comparative Meta-Analysis of Tenofovir Disoproxil Fumarate versus Emtricitabine and Tenofovir Disoproxil Fumarate as Treatments for Patients with Chronic Hepatitis B
    Cui, Guangying
    Xu, Xuejun
    Diao, Hongyan
    SCIENTIFIC REPORTS, 2015, 5
  • [33] Evaluation of Tenofovir Disoproxil Fumarate Treatment in Patients with Chronic Hepatitis B
    Konya, Petek
    Demirturk, Nese
    INFECTIOUS DISEASES AND CLINICAL MICROBIOLOGY, 2022, 4 (01): : 47 - 54
  • [34] Tenofovir disoproxil fumarate versus tenofovir alafenamide on risk of osteoporotic fracture in patients with chronic hepatitis B: A nationwide claims study in South Korea
    Kim, Eunju
    Lee, Hyun Woong
    Kim, Soon Sun
    Yoon, Eileen
    Jang, Eun Sun
    Chang, Jong-In
    Cho, Young Youn
    Seo, Gi Hyeon
    Kim, Hyung Joon
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2023, 58 (11-12) : 1185 - 1193
  • [35] Comparative Meta-Analysis of Tenofovir Disoproxil Fumarate versus Emtricitabine and Tenofovir Disoproxil Fumarate as Treatments for Patients with Chronic Hepatitis B
    Guangying Cui
    Xuejun Xu
    Hongyan Diao
    Scientific Reports, 5
  • [36] Editorial: changes in renal function and bone mineral density after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in chronic hepatitis B patients-author's reply
    Papatheodoridis, George V.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2022, 56 (05) : 918 - 919
  • [37] THE EFFECTS OF ENTECAVIR, TENOFOVIR DISOPROXIL FUMARATE, AND TENOFOVIR ALAFENAMIDE ON THE PROGNOSIS OF TREATMENT-NAIVE PATIENTS WITH CHRONIC HEPATITIS B INFECTIONS
    Chon, Hye Yeon
    Chun, Ho Soo
    Lee, Jae Seung
    Lee, Hye Won
    Kim, Beom Kyung
    Park, Jun Yong
    Kim, Do Young
    Ahn, Sang Hoon
    Sinn, Dong Hyun
    Lee, Jeong-Hoon
    Kim, Seung Up
    HEPATOLOGY, 2020, 72 : 498A - 498A
  • [38] Converting from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide for Treatment of Patients with Hepatitis B Following Liver Transplantation
    Cheng, C.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2020, 20 : 1037 - 1037
  • [39] SWITCHING FROM TENOFOVIR DISOPROXIL FUMARATE TO TENOFOVIR ALAFENAMIDE: ASSESSING THE CHANGE IN RENAL FUNCTION IN HEPATITIS B PATIENTS
    Lee, Minna
    Lee, Susan M. K.
    Bernstein, David Eric
    HEPATOLOGY, 2019, 70 : 316A - 316A
  • [40] EFFECTIVENESS AND SAFETY OF SWITCHING TENOFOVIR DISOPROXIL FUMARATE AND ENTECAVIR TO TENOFOVIR ALAFENAMIDE FUMARATE ( TAF) IN VIROLOGICALLY SUPPRESSED CHRONIC HEPATITIS B VIRUSINFECTED PATIENTS WITH ONEMINUTE OSTEOPOROSIS RISK TEST
    Li, Hui
    Li, Chunmei
    Wei, Jia
    Liu, Yunhua
    Gong, Ming
    Zhang, Ruyi
    Geng, Jiawei
    Wang, Hongyan
    Yu, Zhijian
    Wang, Zi
    Liu, Xiang
    HEPATOLOGY, 2023, 78 : S513 - S513
12345